Last deal

$1.5M

Amount

Post-IPO Equity

Stage

10.01.2018

Date

3

all rounds

$282.05M

Total amount

date founded

Financing round

General

About Company
Argos Therapeutics develops personalized immunotherapies for cancer and infectious diseases.

Industry

Sector :

Subsector :

founded date

01.01.1997

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Founded in 1997, Argos Therapeutics is based in Durham, North Carolina. The company's Arcelis technology platform creates individualized immunotherapies by reprogramming dendritic cells to target specific antigens in each patient's disease. Argos' lead product candidate, AGS-003, is a combination therapy for renal cell carcinoma and other cancers. The company also has a product candidate, AGS-004, for the treatment of HIV. Despite facing financial challenges, including filing for bankruptcy protection in 2018, Argos continues to pursue clinical trials and explore the use of its immunotherapies for various diseases.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Elicio Therapeutics

Elicio Therapeutics

Elicio Therapeutics develops immuno-tumor vaccines to treat cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Cambridge, MA, USA

total rounds

18

total raised

$220.61M
Juvaris BioTherapeutics

Juvaris BioTherapeutics

Juvaris BioTherapeutics develops adjuvanted vaccines and immunotherapeutics to treat cancer and infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Burlingame, CA, USA

total rounds

5

total raised

$63.13M
CoImmune

CoImmune

CoImmune is a biopharmaceutical company that develops personalized immunotherapies for the treatment of cancer and infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Durham, NC, USA

total rounds

2

total raised

$45M
Altor BioScience

Altor BioScience

Altor BioScience develops immunotherapeutic agents for cancer, viral infections and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Miramar Beach, FL, USA

total rounds

12

total raised

$107.69M
M&A Details
1

Acquired by

SCM Life Sciences

announced date

13.02.2019

Financials

Funding Rounds
14
3

Number of Funding Rounds

$282.05M

Money Raised

Their latest funding was raised on 10.01.2018. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
10.01.2018
$1.5M
15.04.2015
$10M
Pharmstandard

Pharmstandard

Pharmstandard is a leading pharmaceutical company in Russia that develops and manufactures modern pharmaceutical products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Manufacturing, Financial Services

Location

Moscow, Russia

count Of Investments

10

count Of Exists

1
Co-Investors
Investors
16
2

Number of lead investors

16

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series C, Series E
No
Series D, Series E
No
Series D, Series E
Forbion

Forbion

Netherlands-based venture capital firm investing in life sciences and MedTech companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Naarden, Netherlands

count Of Investments

165

count Of Exists

68
TVM Capital

TVM Capital

TVM Capital is a venture capital firm that focuses on investing in biopharmaceutical and medical device companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Financial Services, Venture Capital

Location

Munich, Germany

count Of Investments

86

count Of Exists

26
Lumira Ventures

Lumira Ventures

Lumira Ventures is a leading North American healthcare and life sciences venture capital firm.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Toronto, ON, Canada

count Of Investments

90

count Of Exists

10

People

Founders
1
Ralph M. Steinman
Ralph M. Steinman

Ralph M. Steinman

Dr. Steinman received his undergraduate degree from McGill University in 1963 and his M.D. from Harvard Medical School in 1968. After an internship and residency at Massachusetts General Hospital, he joined Rockefeller University in 1970 as a postdoc in the Laboratory of Cellular Physiology and Immunology. He was appointed assistant professor in 1972, associate professor in 1976 and professor in 1988. In 1995 he was named the Henry G. Kunkel Professor, and in 1998 he was appointed director of the Christopher H. Browne Center for Immunology and Immune Diseases. In addition to the Nobel Prize, Dr. Steinman received the Albany Medical Center Prize in Medicine and Biomedical Research in 2009, the Albert Lasker Basic Medical Research Award in 2007, the New York City Mayor's Award for Excellence in Science and Technology in 2004 and the Gairdner Foundation International Award in 2003. He was a member of the National Academy of Sciences and the Institute of Medicine. Dr. Steinman died in 2011.

current job

Argos Therapeutics
Argos Therapeutics

organization founded

1

Ralph M. Steinman

Employee Profiles
32

Joan C. Winterbottom

Chief Human Resources Officer

David W. Gryska

David W. Gryska

Director

Phil Tracy

Phil Tracy

Director

Richard D. Katz,

Chief Financial Officer

Doug Plessinger

Clinical Consultant

Ralph M. Steinman

Ralph M. Steinman

Founder

Lori Harrelson

Vice president, finance

Marilyn French

Director human resources at argos therapeutics

Activity

Recent News
0